To evaluate the efficacy of Rohitakadi vati and Pippali vati orally after Virechana in Non alcoholic fatty liver disease

A Randomized comparative clinical study to evaluate the efficacy of Rohitakadi vati and Pippali vati orally after Virechana in Non-alcoholic fatty liver disease. - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070476

Enrollment

200

Registered

2024-07-11

Start date

Unknown

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E889- Metabolic disorder, unspecified

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1.Clinical signs and symptoms suggesting of NAFLD/Yak?t Roga, that is, pain in right upper quadrant/epigastric region of the abdomen, feeling of nausea, and vomiting, loss of appetite, burning sensation in the abdomen 2.Ultrasonography (USG) abdomen/or other scanning modalities such as contrast-enhanced computed tomography (CECT) abdomen showing fatty infiltration of the liver. USG findings suggestive of fatty liver grade 1, 2, and 3 3.Biochemical: Liver function tests showing raised alanine transaminases (ALT) levels approximately more than 1.5 times the normal limits with/without raised lipid profile and fasting blood glucose levels within normal limits.

Exclusion criteria

Exclusion criteria: 1.Patients in whom alcohol intake exceeded 20 g/day (history of alcohol intake was taken separately from the patients and close relatives) 2.Patients having fasting blood sugar (FBS) =200 mg/dl and postprandial blood sugar (PPBS) =250 mg/dl, despite taking oral hypoglycemic agents, Stage II hypertension, i.e.,systolic blood pressure =160mmHg and diastolic blood pressure =100 mmHg, despite taking antihypertensive drugs 3.Patients with complications of metabolic syndrome such as a cerebrovascular accident, myocardial infarction, chronic kidney disease, suffering from cirrhosis, ascites, variceal hemorrhage, coagulopathy, hepatorenal syndrome, consuming hepatotoxic medicines, alcohol or other narcotic substances.

Design outcomes

Primary

Measure	Time frame
Changes in symptoms of Non alcoholic fatty liver disease- Nausea,Pain abdomen, Burning sensation inabdomen, belching, flatulence, constipation , Changes in Chronic liver disease QuestionnaireTimepoint: 1st assessment-Before treatment (0th day) 2nd assessment- During treatment(31st day) 3rd assessment-(61st day)	—

Secondary

Measure	Time frame
Changes in USG Abdomen, Changes in SGOT,SGPT, Changes in Lipid profile, Changes in BMITimepoint: 1st assessment-Before treatment (0th day) 2nd assessment- During treatment(31st day) 3rd assessment-(61st day)	—

Countries

India

Contacts

Public ContactDr Harshitha K S

Government Ayurveda Medical College, Mysuru

mythreyrc@gmail.com8618570803

Outcome results